NextPharma to sell logistics arm to Cencora

13 October 2025

European pharmaceutical contractdevelopment and manufacturing organisation (CDMO), NextPharma has entered into an agreement with Cencora, a USA-based pharmaceutical solutions organization, to sell NextPharma’s healthcare logistics services business, NextPharma Logistics GmbH.

The transaction is expected to complete in the fourth quarter of 2025, subject to customary regulatory approvals. Terms of the transaction are not being disclosed.

The divestment forms part of NextPharma’s strategic focus on strengthening its position as a leading European CDMO, dedicated to delivering the highest quality products and services to its customers. As part of this plan, the NextPharma Logistics business - which provides pre-wholesaling and logistics services for a range of pharmaceutical and animal health clients from facilities in Germany, Austria, and Switzerland - has been identified as non-core to the Company’s long-term strategy, which is centred on commercial manufacturing and product development. With approximately 230 employees, NextPharma Logistics has built a strong reputation in its field.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK